Skip to main content

Advertisement

SpringerLink
Log in

Diagnosis, Management, and Prevention of Hepatitis B Reactivation

  • Hepatitis B (J Lim, Section Editor)
  • Published:
Current Hepatology Reports Aims and scope Submit manuscript

Abstract

Chronic hepatitis B (CHB) is a global public health problem and is the leading cause of cirrhosis and liver cancer worldwide. Despite significant morbidity and mortality of CHB, there remains lack of knowledge and awareness in screening patients at risk. HBV reactivation is well documented in patients previously exposed to HBV receiving immunosuppressive agents and is characterized by a rise in serum HBV DNA with ALT elevation. The delayed recognition of reactivation can lead to significant clinical consequences, including liver failure and death, and can be prevented with antiviral treatment. The challenges surrounding the management of HBV reactivation include a lack of awareness of this phenomenon, heterogeneity in clinical practice for CHB, and a paucity of data to guide clinicians in the prevention and treatment of reactivation. Collaboration and partnership across medical specialties will be essential in the development of consensus guidelines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. World Health Organization. Hepatitis B. Geneva, Switzerland: World Health Organization. 2012. Available at: http://www.who.int/mediacentre/factsheets/fs204/en/. Accessed 1 April 2013.

  2. Pungpapong S, Kim WR, Poterucha JJ. Natural history of hepatitis B virus infection: an update for clinicians. Mayo Clin Proc. 2007;82:967–75.

    Article  CAS  PubMed  Google Scholar 

  3. Weinbaum CM et al. MMWR Recomm Rep. 2008;57(RR-8):1–20.

    PubMed  Google Scholar 

  4. Kowdley KV, Wang CC, Se W, et al. Prevalence of chronic hepatitis B among foreign-born persons living in the United States by country of origin. Hepatology. 2012;56:422–33.

    Article  PubMed  Google Scholar 

  5. Kim WR. Epidemiology of hepatitis B in the United States. Hepatology. 2009;49(5 Suppl):S28–34.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Wasley A, Kruszon-Moran D, Kuhnert W, Simard EP, Finelli L, McQuillan G, et al. The prevalence of hepatitis B virus infection in the United States in the era of vaccination. J Infect Dis. 2010;202:192–201.

    Article  PubMed  Google Scholar 

  7. Lin SY, Chang ET, So SK. Why we should routinely screen Asian American adults for hepatitis B: a cross-sectional study of Asians in California. Hepatology. 2007;46:1034–40.

    Article  PubMed  Google Scholar 

  8. Asian Liver Center at Stanford University. Physician’s guide to hepatitis B. 2013. http://liver.stanford.edu/media/publications/Handbook/2013Handbook.pdf. Accessed 18 Oct. 2013.

  9. U.S. Food and Drug Administration. FDA drug safety communication: boxed warning and new recommendations to decrease risk of hepatitis B reactivation with the immune suppressing and anticancer drugs Arzerra (ofatumumab) and Rituxan (rituximab) 2013. http://www.fda.com/Drugs/DrugSafety/ucm366406.htm.

  10. American Association for the Study of Liver Diseases emerging trends conference, reactivation of hepatitis B, March 21–22, 2013, (Arlington, VA 2013).

  11. Hoofnagle J. Reactivation of hepatitis B. Hepatology. 2009;49(5):S156–65.

    Article  CAS  PubMed  Google Scholar 

  12. Yang PL, Althage A, Chung J, Maier H, et al. Immune effectors required for hepatitis B virus clearance. Proc Natl Acad Sci U S A. 2010;107:798–802.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Lok ASF, Liang RHS, Chiu EKW, Wong KL, et al. Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology. 1991;100:182–8.

    CAS  PubMed  Google Scholar 

  14. Markovic S, Drozina G, Volk M, Fidler-Jenko M. Reactivation of hepatitis B but not hepatitis C in patients with malignant lymphoma and immunosuppressive therapy. A prospective study in 305 patients. Hepatogastroenterology. 1999;46:2925.

    CAS  PubMed  Google Scholar 

  15. Hoofnagle JH, Dusheiko GM, Schafer DF, et al. Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med. 1982;96:447. One of the earliest reports of severe reactivation of hepatitis B infection in context of immunosuppression following cancer chemotherapy.

    Article  CAS  PubMed  Google Scholar 

  16. Lau JY, Lai CL, Lin HJ, et al. Fatal reactivation of chronic hepatitis B virus infection following withdrawal of chemotherapy in lym- phomapatients. Q J Med. 1989;73:911.

    CAS  PubMed  Google Scholar 

  17. Thung SN, Gerber MA, Klion F, Gilbert H. Massive hepatic necrosis after chemotherapy withdrawal in a hepatitis B virus carrier. Arch Intern Med. 1985;145:1313.

    Article  CAS  PubMed  Google Scholar 

  18. Yeo W, Chan PK, Hui P, et al. Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol. 2003;70:533–6.

    Article  Google Scholar 

  19. Yun J, Kim KH, Kang ES, et al. Prophylactic use of lamivudine for hepatitis B exacerbation in post-operative breast cancer patients receiving anthracycline-based adjuvant chemotherapy. Br J Cancer. 2011;104:559–63.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  20. Yeo W et al. Frequency of hepatitis B reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62:299–307.

    Article  CAS  PubMed  Google Scholar 

  21. Yeo W et al. Comprehensive analysis of risk factors associating with hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy. Br J Cancer. 2004;90:1306–11.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  22. Ling WH, Soe PP, Pang AS, et al. Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours. Br J Cancer. 2013;108:1931–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Hui CK, Cheung WW, Zhang HY, Au WY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients under- going cytotoxic chemotherapy. Gastroenterology. 2006;131:59–68.

    Article  CAS  PubMed  Google Scholar 

  24. Yeo W et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol. 2009;27:605–11. One of several important reports which definitively identified rituximab as a key predictor of HBV reactivation risk among individuals undergoing cancer chemotherapy.

    Article  CAS  PubMed  Google Scholar 

  25. Hsu C, Tsou H-h, Lin S-J, on behalf of the Taiwan Cooperative Oncology Group, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology. 2014;59:2092–100. One of several important reports which defined the risk of severe HBV reactivation in patients with resolved HBV infection.

    Article  CAS  PubMed  Google Scholar 

  26. Dong H-J, Ni L-N, Sheng G-F, et al. Risk of hepatitis B (HBV) reactivation in non-Hodgkin lymphoma patients receiving rituxi- mab-chemotherapy: a meta-analysis. J Clin Virol. 2013;57:209–14.

    Article  CAS  PubMed  Google Scholar 

  27. Hoofnagle JH, Davis GL, Pappas SC, et al. A short course of prednisolone in chronic type B hepatitis. Report of a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 1986;104:12–48.

    Article  CAS  PubMed  Google Scholar 

  28. Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci U S A. 1986;83:1627–31.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  29. Perillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon Alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. N Engl J Med. 1990;323:295–301.

    Article  Google Scholar 

  30. Cheng AL, Hsiung CA, Su IJ, Chen PJ, Chang MC, et al. Steroid free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology. 2003;37:1320–8.

    Article  CAS  PubMed  Google Scholar 

  31. Lau GKK, Liang R, Chiu EKW, Lee CK, Lam SK. Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study. Bone Marrow Transplant. 1997;19:795–9.

    Article  CAS  PubMed  Google Scholar 

  32. Martin BA, Rowe JM, Bouides PA, DiPersio JF. Hepatitis B reactivation following allogeneic bone marrow transplantation: case report and review of the literature. Bone Marrow Transplant. 1995;15:145–8.

    CAS  PubMed  Google Scholar 

  33. Vigano M, Vener C, Lampertico P, et al. Risk of hepatitis B surface antigen seroconversion after allogeneic hematopoietic SCT. Bone Marrow Transplant. 2011;46:125–31.

    Article  CAS  PubMed  Google Scholar 

  34. Park S, Kim K, Kim DH, et al. Changes of hepatitis B virus serologic status after allogeneic hematopoietic stem cell transplantation and impact of donor immunity on hepatitis B virus. Biol Blood Marrow Transplant. 2011;17:1630–7.

    Article  PubMed  Google Scholar 

  35. Ramos CA, Saliba RM, de Padua SL, et al. Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2010;16:686–94.

    Article  CAS  PubMed  Google Scholar 

  36. Hammond S, Borchelt AM, Ukomadu C, et al. Hepatitis B virus reactivation following allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15:1049–59.

    Article  PubMed  Google Scholar 

  37. Onozawa M, Hashino S, Darmanin S, et al. HB vaccination in the prevention of viral reactivation in allogeneic hematopoietic stem cell transplantation recipients with previous HBV infection. Biol Blood Marrow Transplant. 2008;14:1226–30.

    Article  PubMed  Google Scholar 

  38. Uhm JE, Kim K, Lim TK, et al. Changes in serologic markers of hepatitis B following autologous hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2007;13:463–8.

    Article  CAS  PubMed  Google Scholar 

  39. Knoll A, Boehm S, Hahn J, et al. Long-term surveillance of haematopoietic stem cell recipients with resolved hepatitis B: high risk of viral reactivation even in a recipient with a vaccinated donor. J Viral Hepat. 2007;14:478–83.

    Article  CAS  PubMed  Google Scholar 

  40. Dhedin N, Douvin C, Mathieu K, et al. Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation; a retrospective study of 37 patients with pretransplant anti-HBs and anti- HBc. Transplantation. 1998;66:616–9.

    Article  CAS  PubMed  Google Scholar 

  41. Kempinska A, Kwak EJ, Angel JB. Reactivation of hepatitis B infection following allogeneic bone marrow transplantation in a hepatitis B- immune patient: case report and review of the literature. Clin Infect Dis. 2005;41(9):127–82.

    Google Scholar 

  42. Le Q et al. Biol Blood Marrow Transplant. 2009;15(7):886–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  43. Webster A, Brenner MK, Prentice HG, et al. Fatal hepatitis B reactivation after autologous bone marrow transplantation. Bone Marrow Transplant. 1989;4:207–8.

    CAS  PubMed  Google Scholar 

  44. Fan FS, Tzeng CH, Yeh HM, Chen PM. Reverse seroconversion of hepatitis B virus infections status after allogeneic bone marrow transplantation from a carrier donor. Bone Marrow Transplant. 1992;10:189–91.

    CAS  PubMed  Google Scholar 

  45. Grossi P et al. Prevalence and outcome of hepatitis B virus (HBV) infection following thoracic organ transplantation. J Heart Lung Transplant. 2001;20:179.

    Article  PubMed  Google Scholar 

  46. Lunel F et al. Hepatitis virus infections in heart transplant recipients: epidemiology, natural history, characteristics, and impact on survival. Gastroenterology. 2000;119:1064–74.

    Article  CAS  PubMed  Google Scholar 

  47. Shitrit AB et al. Lamivudine prophylaxis for hepatitis B virus infection after lung transplantation. Ann Thorac Surg. 2006;81:185102.

    Article  Google Scholar 

  48. Zampino R et al. Heart transplantation in patients with chronic hepatitis B: clinical evolution, molecular analysis, and effect of treatment. Transplantation. 2005;80:1340–3.

    Article  CAS  PubMed  Google Scholar 

  49. Liu CJ et al. Lamivudine treatment for hepatitis B reactivation in HBsAg carriers after organ transplantation: a 4 years experience. J Gastroenterol Hepatol. 2001;16:1001–8.

    Article  CAS  PubMed  Google Scholar 

  50. Dusheiko G et al. Natural history of hepatitis B virus infection in renal transplant recipients—A 15 years follow up. Hepatology. 1983;3:330–6.

    Article  CAS  PubMed  Google Scholar 

  51. Mathurin P et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999;29:257–63.

    Article  CAS  PubMed  Google Scholar 

  52. Kalia H, Fabrizi F, Martin P. Hepatitis B virus and renal transplantation. Transplant Rev (Orlando). 2011;25:102–9.

    Article  Google Scholar 

  53. Knoll A, Pietrzyk M, Loss M, Goetz WA, Jilg W. Solid-organ transplantation in HBsAg-negative patients with antibodies to HBV core antigen: low risk of HBV reactivation. Transplantation. 2011;79:1631–3.

    Article  Google Scholar 

  54. Kanaan et al. J Clin Virol. 2012;55:233–8.

    Article  PubMed  Google Scholar 

  55. Vallet-Pichard A et al. J Hepatol. 2011;55:474–82.

    Article  PubMed  Google Scholar 

  56. Chung SJ, Kim JK, Park MC, Park YB, Lee SK. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following antitumor necrosis factor- alpha therapy. J Rheumatol. 2009;36:2416–20.

    Article  CAS  PubMed  Google Scholar 

  57. Zingarelli S, Frassi M, Bazzani C, Scarsi M, Puoti M, et al. Use of tumor necrosis factor-alpha-blocking agents in hepatitis B virus- positive patients: reports of 3 cases and review of the literature. J Rheumatol. 2009;36:1188–94.

    Article  CAS  PubMed  Google Scholar 

  58. Guidotti LG, Ishikawa T, Hobbs MV, Matzke B, et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity. 1996;4:25–36.

    Article  CAS  PubMed  Google Scholar 

  59. LeFevre ML. US preventive services task force. Screening for hepatitis B virus infection in nonpregnant adolescents and adults: U.S. Preventive services task force recommendation statement. Ann Intern Med. 2014;161:58–66.

    Article  PubMed  Google Scholar 

  60. ArtzAS SMR, Feld JJ, et al. American society of clinical oncology provisional clinical opinion: chronic hepatitis B virus infection screening in patients receiving cytotoxic chemotherapy for treatment of malignant diseases. J Clin Oncol. 2010;28(28):3199–202.

    Article  Google Scholar 

  61. Sheron N, Lau JY, Daniels HM, Webster J, et al. Tumor necrosis factor to treat chronic hepatitis B virus infection. Lancet. 1990;336:321–2.

    Article  CAS  PubMed  Google Scholar 

  62. Esteve M, Saro C, Gonzalez-Huix F, et al. Chronic hepatitis B reactivation following Infliximab therapy in Crohn’s disease patients: need for primary prophylaxis. Gut. 2004;53:1363.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  63. Kuwabara H, Fukua A, Tsuda Y, Shibayama Y. Precore mutant hepatitis B virus-associated fulminant hepatitis during Infliximab therapy for rheumatoid arthritis. Clin Rheumatol. 2010. doi:10.1007/s10067-010-1438-y.

    PubMed Central  PubMed  Google Scholar 

  64. Ramos-Casais M. Therapy: are TNF blockers safe for patients with hepatitis B virus infection? Nat Rev Rheuamtol. 2010;6:618–20.

    Article  Google Scholar 

  65. Abramson A, Menter A, Perillo R. Psoriasis, hepatitis B and the tumor necrosis factor-alpha inhibitor agents: a review and recommendations for management. J Am Acad Dermatol. 2012;67(6):1349–61.

    Article  CAS  PubMed  Google Scholar 

  66. Loras C, Gisbert IP, Minguez M, Merino O, et al. Liver dysfunction related to hepatitis B and C in patients with inflammatory bowel disease treated with immuosuppressive therapy. Gut. 2010;59:1340–6.

    Article  CAS  PubMed  Google Scholar 

  67. Colbert C, Chavarria A, Berkelhammer C. Fulminant hepatic failure in chronic hepatitis B on withdrawal of corticosteroids, azathi- oprine and Infliximab for Crohn’s disease. Inflamm Bowel Dis. 2007;13:1453–4.

    Article  PubMed  Google Scholar 

  68. Zhou H. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. J Clin Pharmacol. 2005;45:490–7.

    Article  CAS  PubMed  Google Scholar 

  69. Perez-Alvarez R, Diaz-Lagares C, Garcia-Hernandez F, et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF) targeted therapy: analysis of 257 case. Medicine (Baltimore). 2011;90:359–71.

    Article  CAS  Google Scholar 

  70. Papa A, Felic C, Marzo M, et al. Prevalence and natural history of hepatitis B and C infections in large population of IBD patients treated with anti-tumor necrosis factor-alpha agents. J Crohn’s Colitis. 2013;7:113–9.

    Article  Google Scholar 

  71. Charpin C, Guis S, Colson P, et al. Safety of TNF-blocking agents in rheumatic patients with serology suggesting past hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther. 2009;11:R179.

    Article  PubMed Central  PubMed  Google Scholar 

  72. Mori S. Past hepatitis B virus infection in rheumatoid arthritis patients receiving biological and/ or nonbiological disease-modifying antirheumatic drugs. Mod Rheumatol. 2011;21:621–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  73. Lee YH, Bae SC, Song GG. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin Exp Rheumatol. 2012;31:118–21.

    CAS  PubMed  Google Scholar 

  74. Carroll MB, Forgione MA. Use of tumor necrosis factor alpha inhibitors in hepatitis B surface antigen-positive patients: a literature review and potential mechanisms of action. Clin Rheumatol. 2010;29:1021–9.

    Article  PubMed  Google Scholar 

  75. NIH consensus development conference statement on management of hepatitis B. volume 25, number 2. October 20–22, 2008. http:// www.ahrq.gov/clinic/tp/hepbtp.htm.

  76. Institute of Medicine. Hepatitis and liver cancer: a national strategy for prevention and control of hepatitis B and C. Washington DC: National Academies Pr; 2010. Accessed at www.iom.edu/Reports/2010/Hepatitis-and-Liver-Cancer-A-National-Strategy-for-Prevention-and-Control-of-Hepatitis-B-and-C.aspx.

  77. Dibisceglie A, Lok AS, Martin P, Terrault N, Perrillo R, et al. Recent US food and drug administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology. 2015;61:703–11.

    Article  CAS  Google Scholar 

  78. EASL. EASL practice guidelines. J Hepatol. 2012;57:167–85.

    Article  Google Scholar 

  79. Hwang J, Fisch M, Zhang H, et al. Low rates of hepatitis B virus screening at the onset of chemotherapy. J Oncol Pract. 2012;8(4):e32–9.

    Article  PubMed Central  PubMed  Google Scholar 

  80. Paul S, Shuja A, Tam I, Kim E, et al. Hepatitis B virus screening rates are sub-optimal in patients receiving immunosuppressive therapy. Hepatology. 2014;60(4 suppl):A1669.

    Google Scholar 

  81. Stine A, Stine A, et al. Rheumatologists’ awareness of and screening practices for hepatitis B virus infection prior to initiating immunomodulatory therapy. Arthritis Care Res. 2010;62:704–11. Stine A et al. South Med J 2011; 104:781–788; 18.

  82. Lau GK, Yiu HH, Fong DY, Cheng HC, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology. 2003;125:1742–9.

    Article  CAS  PubMed  Google Scholar 

  83. Jang JW, Choi JY, Bae SH, Hwang WS, et al. A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemolipiodolization. Hepatology. 2006;43:233–40.

    Article  CAS  PubMed  Google Scholar 

  84. Hsu C, Hsiung CA, Su IJ, Hwang WS, Wang MC, et al. A revisit for prophylactic lamivudine for chemotherapy-associated hepatitis B reactivation in non-Hodgkin’s lymphoma: a randomized trial. Hepatology. 2008;47:844–53.

    Article  CAS  PubMed  Google Scholar 

  85. Loomba R, Rowley A, Wesley R, et al. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med. 2008;148:519–28. Important systematic review summarizing data evaluating the effect of preemptive antiviral therapy on incidence of HBV reactivation in context of cancer chemotherapy.

    Article  PubMed Central  PubMed  Google Scholar 

  86. Li HR, Huang JJ, Guo HQ, Zhang X, et al. J Viral Hepat. 2011;18:877–83.

    Article  PubMed  Google Scholar 

  87. Yoo JJ. Proceedings of the hepatology. Hoboken NJ: Wiley- Blackwell; 2012. p. 631A.

    Google Scholar 

  88. Kim SJ, Hsu C, Song YQ, Tay K, et al. Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia lymphoma study group. Eur J Cancer. 2013;49:3486–96.

    Article  CAS  PubMed  Google Scholar 

  89. Huang YH, Hsiao LT, Hong YC, Chiou TJ, et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol. 2013;31:2765–72.

    Article  CAS  PubMed  Google Scholar 

  90. Martyak LA, Taqavi E, Saab S. Lamivudine prophylaxis is effective in reducing hepatitis B reactivation and reactivation-related mortality in chemotherapy patients: a meta-analysis. Liver Int. 2008;28:28–38.

    Article  CAS  PubMed  Google Scholar 

  91. Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int. 2012;6:531–61.

    Article  PubMed  Google Scholar 

  92. Singh J, Furst D, Bharat A, Curtis JR, Kavanaugh AF, Kremer J, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Rheum. 2008;59(6):762–84.

    Article  Google Scholar 

  93. Reddy KR, Beavers KL, Hammond SP, Lim JK, Falck-Ytter YT, American Gastroenterological Association Institute. American gastroenterological association institute guidelines on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology. 2015;148:215–9. Important evidence-based consensus guideline by a major specialty society providing guidance for clinicians in identifying and treating patients at risk for HBV reactivation in context of immunosuppressive drug therapy.

    Article  CAS  PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Hannah M. Lee, Ann Marie Liapakis, and Joseph K. Lim declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Asian Pacific Liver Health Clinic, Division of Gastroenterology/Hepatology, Tufts University School of Medicine, Boston, MA, USA

    Hannah M. Lee

  2. Yale Liver Center, Section of Digestive Diseases, Yale University School of Medicine, 333 Cedar Street, LMP 1080, New Haven, CT, 06520-8019, USA

    AnnMarie Liapakis & Joseph K. Lim

Authors
  1. Hannah M. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. AnnMarie Liapakis
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joseph K. Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joseph K. Lim.

Additional information

This article is part of the Topical Collection on Hepatitis B

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, H.M., Liapakis, A. & Lim, J.K. Diagnosis, Management, and Prevention of Hepatitis B Reactivation. Curr Hepatology Rep 14, 184–194 (2015). https://doi.org/10.1007/s11901-015-0271-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11901-015-0271-9

Keywords

Search

Navigation